June 1995 in “International Journal of Gynecology & Obstetrics”
The new method showed that endometriotic tissue has lower estrogen receptor levels but similar progesterone levels compared to normal endometrium, with both following a similar cycle.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.